SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Sonoma Pharmaceuticals, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.12+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $4.31M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.71 (−70.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Sonoma Pharmaceuticals, Inc. grew revenue 47.0% to $21.92M over the twelve months to Jun 30, 2026. Free cash flow was -$2.66M.
Revenue
$21.92M
+47.0% vs. a year earlier
Operating income
-$1.41M
TTM Q1 2027
Free cash flow
-$2.66M
TTM Q1 2027
EPS, diluted
-$1.22
TTM Q1 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.31M
- P/E ratio
- –
- Price to sales
- 0.20
- Price to book
- 0.65
- Dividend yield
- –
- Free cash flow yield
- -61.64%
Fundamentals
- Revenue
- $21.92M
- Net income
- -$2.26M
- EPS, diluted
- -$1.22
- Free cash flow
- -$2.66M
- Book value per share
- $1.71
- Diluted shares
- 4M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$21.92M+47.0% YoY
Gross profit
$8.53M+51.7% YoY
Operating income
-$1.41M
Net income
-$2.26M
EPS, diluted
-$1.22
Free cash flow
-$2.66M
Reported periodTrailing twelve months